BioSpace News Archive

EKIMAS Corporation, formerly AdvanSource Biomaterials Corporation, which sold substantially all of its assets to Mitsubishi Chemical Performance Polymers, Inc. on January 31, 2020, announced that the Company’s Board of Directors approved a special cash distribution of $0.18 per share at its April 3, 2020 meeting.

RTI International has closed on its acquisition of Medical Data Analytics (MDA), a provider of real-world evidence (RWE) generation to the pharmaceutical and biotechnology industry

America’s Blood Centers and its members are working closely with the U.S. Food and Drug Administration to collect and distribute convalescent plasma from individuals who have recovered from COVID-19..

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has finalized a settlement with the Department of Justice (the “DOJ”), resolving an investigation concerning the accuracy of commercial pricing disclosures to the United States Department of Veterans Affairs

Number of Patients Using Home Dialysis Increases Almost 15 Percent In Past Year

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

Golfers Against Cancer takes pride in identifying research projects dedicated to specific work targeting various forms of cancer.

Provides Preliminary Revenue Range for the First Quarter 2020 and Withdraws Prior Annual Revenue Guidance for 2020 Due to COVID-19 Impact

Invitae Corporation announced the closing of its underwritten public offering of 20,444,444 shares of its common stock, including 2,666,666 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, at the public offering price of $9.00 per share.

Ridgeback Biotherapeutics LP and Drug Innovations at Emory, LLC, announced that the U.S. Food and Drug Administration has approved an Investigational New Drug application by Drug Innovation Ventures at Emory, LLC, wholly owned by Emory University, for an orally available antiviral compound, EIDD-2801, exclusively licensed to Ridgeback Biotherapeutics, LP, a closely held biotechnology company.